Camurus AB

Camurus AB

Health CarePharmaceuticals & Biotechnology
  • Price (SEK)73.00
  • Today's Change0.00 / 0.00%
  • Shares traded8.49k
  • 1 Year change-30.55%
  • Beta1.6056
Data delayed at least 15 minutes, as of Apr 18 2019 12:30 BST.
More ▼

Profile data is unavailable for this security.

About the company

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

  • Revenue in SEK (TTM)49.32m
  • Net income in SEK-234.68m
  • Incorporated--
  • Employees94.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Alligator Bioscience AB26.96m-150.04m1.82bn55.00--3.88--67.39-2.10-2.100.37776.560.0468--0.6875490,181.80-26.07---27.63-------556.54------0.00---52.60---135.33------
Infant Bacterial Therapeutics AB0.00-40.61m2.06bn8.00--3.83-----3.77-3.770.0049.590.00----0.00-11.00-17.29-11.20-18.00-------28,727.13---33.120.00---100.00---12.31------
Orexo AB783.10m137.90m2.45bn53.0017.995.1515.433.133.943.9422.4913.780.68380.81083.2414,775,470.0012.04-1.4418.93-2.1078.0677.8017.61-2.281.8342.220.4024--21.6612.77494.40---43.66--
IRLAB Therapeutics AB18.00k-74.10m2.67bn25.00--12.66--148,079.20-9.74-9.740.002426.230.00009--1.89720.00-38.20---40.33-------411,655.60-----367.650.00---83.49---31.79------
Nordic Nanovector ASA0.00-369.16m2.76bn38.00--6.30-----6.87-6.870.007.330.00----0.00-53.87-34.38-64.35-38.09-------73,984.18----0.00---100.00---14.96--48.77--
Immunovia AB (publ)332.60k-86.54m2.90bn45.00--7.07--8,705.89-4.67-4.670.017923.650.0009--0.03317,391.11-23.77-17.94-24.77-18.78-11,993.78-5,071.06-26,018.83-13,304.19----0.00--123.28-22.36-91.32--81.72--
Camurus AB49.32m-234.68m3.53bn94.00--12.13--71.49-5.67-5.671.196.020.11731.0212.24524,691.50-55.83---73.64--86.17---475.81--1.40--0.00---9.18---23.14------
Oriola Oyj16.24bn132.89m4.74bn2.71k35.742.5012.300.29160.070.078.551.001.685.717.75573,577.301.373.514.5311.3122.4621.430.81832.170.41826.130.416247.581.60-0.8477-51.15-5.89-5.36--
Data as of Apr 18 2019. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK

Institutional shareholders

17.23%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 02 Apr 20193.00m6.25%
Max Mitteregger Kapitalf�rvaltning ABas of 31 Jan 20192.73m5.68%
Catella Fondf�rvaltning ABas of 28 Feb 2019835.99k1.74%
Swedbank Robur Fonder ABas of 31 Mar 2019706.46k1.47%
Enter Fonder ABas of 28 Dec 2018443.32k0.92%
SEB Investment Management ABas of 30 Jun 2018187.26k0.39%
Xact Kapitalf�rvaltning ABas of 31 Mar 2019182.35k0.38%
Andra AP-fondenas of 30 Jun 2018158.03k0.33%
Skandia Investment Management ABas of 28 Feb 201915.21k0.03%
Nordic Cross Asset Management ABas of 05 Apr 201914.88k0.03%
More ▼
Data from 31 Dec 2016 - 05 Apr 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.